Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2019 Filed Nov 4, 2019 21:15 UTC |
Kearney Terrence CDirector
|
SaleCommon Stock | 3,159 | $200.00 | $631,800.00 |
DisclosureSEC source: 0001209191-19-054882 · doc4.xml · nonDerivative · entry 2 Kearney Terrence C · CIK 0001289098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,811 F1 · kind: Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 21:13 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,879 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · derivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,210 Underlying: Common Stock · 8,879 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 21:13 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 8,879 | $200.00 | $1,775,800.00 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,287 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 21:13 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionCommon Stock | 8,879 | $131.89 | $1,171,051.31 |
DisclosureSEC source: 0001209191-19-054876 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 21:15 UTC |
Kearney Terrence CDirector
|
SaleCommon Stock | 1,841 | $200.00 | $368,200.00 |
DisclosureSEC source: 0001209191-19-054882 · doc4.xml · nonDerivative · entry 1 Kearney Terrence C · CIK 0001289098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,970 F1 · kind: Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 20:36 UTC |
Kewalramani ReshmaEVP and CMO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,057 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-19-054635 · doc4.xml · derivative · entry 3 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,096 Underlying: Common Stock · 3,057 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 20:36 UTC |
Kewalramani ReshmaEVP and CMO
|
SaleCommon Stock | 3,057 | $199.00 | $608,343.00 |
DisclosureSEC source: 0001209191-19-054635 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,098 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 20:36 UTC |
Kewalramani ReshmaEVP and CMO
|
Exercise / conversionCommon Stock | 3,057 | $155.57 | $475,577.49 |
DisclosureSEC source: 0001209191-19-054635 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2019 Filed Oct 29, 2019 20:54 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,311 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-19-054333 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,311 Underlying: Common Stock · 4,311 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| October 25, 2019 Filed Oct 29, 2019 20:54 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 4,311 | $195.01 | $840,688.11 |
DisclosureSEC source: 0001209191-19-054333 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $195.01 (range $195.00 to $195.04). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 25, 2019 Filed Oct 29, 2019 20:54 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionCommon Stock | 4,311 | $91.05 | $392,516.55 |
DisclosureSEC source: 0001209191-19-054333 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:13 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,669 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-19-053923 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,229 Underlying: Common Stock · 3,669 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:13 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 3,669 | $194.37 | $713,143.53 |
DisclosureSEC source: 0001209191-19-053923 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,553 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:13 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 3,669 | $155.57 | $570,786.33 |
DisclosureSEC source: 0001209191-19-053923 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:18 UTC |
Kewalramani ReshmaEVP and CMO
|
SaleCommon Stock | 638 | $189.00 | $120,582.00 |
DisclosureSEC source: 0001209191-19-053925 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,098 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 35,411 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · derivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,089 Underlying: Common Stock · 35,411 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 72,420 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · derivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,580 Underlying: Common Stock · 72,420 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 35,411 | $190.00 | $6,728,090.00 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,287 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionCommon Stock | 35,411 | $131.89 | $4,670,356.79 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 72,420 | $190.00 | $13,759,800.00 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,287 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:23 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionCommon Stock | 72,420 | $109.14 | $7,903,918.80 |
DisclosureSEC source: 0001209191-19-053936 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:26 UTC |
MCGLYNN MARGARET GDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-19-053941 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:26 UTC |
MCGLYNN MARGARET GDirector
|
SaleCommon Stock | 20,000 | $190.00 | $3,800,000.00 |
DisclosureSEC source: 0001209191-19-053941 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,124 F1 · kind: Transaction made pursuant to Ms. McGlynn's company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:26 UTC |
MCGLYNN MARGARET GDirector
|
Exercise / conversionCommon Stock | 20,000 | $72.14 | $1,442,800.00 |
DisclosureSEC source: 0001209191-19-053941 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:28 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,883 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-19-053945 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 3,883 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:28 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 3,883 | $190.27 | $738,818.41 |
DisclosureSEC source: 0001209191-19-053945 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $190.27 (range $190.00 to $190.60). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 23:28 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionCommon Stock | 3,883 | $86.52 | $335,957.16 |
DisclosureSEC source: 0001209191-19-053945 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 20:29 UTC |
Parini MichaelEVP, CL&AO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,250 | $0.00 Strike: $122.45 | $0.00 |
DisclosureSEC source: 0001209191-19-053698 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 01/04/2016. Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 20:29 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 4,250 | $177.80 | $755,650.00 |
DisclosureSEC source: 0001209191-19-053698 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 20:29 UTC |
Parini MichaelEVP, CL&AO
|
Exercise / conversionCommon Stock | 4,250 | $122.45 | $520,412.50 |
DisclosureSEC source: 0001209191-19-053698 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 20:07 UTC |
SACHS BRUCE IDirector
|
GrantDeferred Stock Units · Derivative | 263.533 | $175.50 | $46,250.04 |
DisclosureSEC source: 0001209191-19-053410 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,898.816 Underlying: Common Stock · 263.533 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:14 UTC |
Parini MichaelEVP, CL&AO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-19-053284 · doc4.xml · derivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,375 Underlying: Common Stock · 2,125 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:14 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 100 | $175.10 | $17,510.00 |
DisclosureSEC source: 0001209191-19-053284 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:14 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 1,136 | $174.46 | $198,186.56 |
DisclosureSEC source: 0001209191-19-053284 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,103 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $174.46 (range $174.07 to $174.90). Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:14 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 889 | $173.44 | $154,188.16 |
DisclosureSEC source: 0001209191-19-053284 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,239 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $173.44 (range $172.81 to $173.77). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:14 UTC |
Parini MichaelEVP, CL&AO
|
Exercise / conversionCommon Stock | 2,125 | $90.29 | $191,866.25 |
DisclosureSEC source: 0001209191-19-053284 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 20:25 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 444 | $167.69 | $74,454.36 |
DisclosureSEC source: 0001209191-19-052177 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,252 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 20:11 UTC |
Bhatia Sangeeta N.Director
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 5,818 | $0.00 Strike: $126.68 | $0.00 |
DisclosureSEC source: 0001209191-19-052541 · doc4.xml · derivative · entry 7 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,729 Underlying: Common Stock · 5,818 shares Expires 2025-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 20:11 UTC |
Bhatia Sangeeta N.Director
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 1,270 | $0.00 Strike: $125.71 | $0.00 |
DisclosureSEC source: 0001209191-19-052541 · doc4.xml · derivative · entry 6 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,907 Underlying: Common Stock · 1,270 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 20:11 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 1,232 | $167.88 | $206,828.16 |
DisclosureSEC source: 0001209191-19-052541 · doc4.xml · nonDerivative · entry 5 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,249 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $167.88 (range $167.50 to $168.36). Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 20:11 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 5,187 | $166.82 | $865,295.34 |
DisclosureSEC source: 0001209191-19-052541 · doc4.xml · nonDerivative · entry 4 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,481 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $166.82 (range $166.40 to $167.35). Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 20:11 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 1,960 | $166.08 | $325,516.80 |
DisclosureSEC source: 0001209191-19-052541 · doc4.xml · nonDerivative · entry 3 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,668 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $166.08 (range $165.39 to $166.38). F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 20:11 UTC |
Bhatia Sangeeta N.Director
|
Exercise / conversionCommon Stock | 5,818 | $126.68 | $737,024.24 |
DisclosureSEC source: 0001209191-19-052541 · doc4.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 20:11 UTC |
Bhatia Sangeeta N.Director
|
Exercise / conversionCommon Stock | 1,270 | $125.71 | $159,651.70 |
DisclosureSEC source: 0001209191-19-052541 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:25 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 188 | $169.11 | $31,792.68 |
DisclosureSEC source: 0001209191-19-052177 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,696 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 20:30 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock (right to buy) · Derivative | 4,659 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-19-046807 · doc4.xml · derivative · entry 11 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,980 Underlying: Common Stock · 4,659 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 20:30 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,592 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-19-046807 · doc4.xml · derivative · entry 10 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,592 Underlying: Common Stock · 3,592 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 20:30 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,250 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-046807 · doc4.xml · derivative · entry 9 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,250 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 20:30 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 2,330 | $186.37 | $434,242.10 |
DisclosureSEC source: 0001209191-19-046807 · doc4.xml · nonDerivative · entry 8 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,553 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 20:30 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 2,329 | $186.41 | $434,148.89 |
DisclosureSEC source: 0001209191-19-046807 · doc4.xml · nonDerivative · entry 7 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,883 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.